Vanguard Global Advisers’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
Other funds holding FHTX
EC
SL
Vanguard Global Advisers's FHTX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Foghorn Therapeutics (FHTX) stake by 1.3% in Q3 2026, buying an estimated $906 and bringing the position to 13,005 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.
Vanguard Global Advisers first reported a position in FHTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $62.6K in Q2 2026. 122 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.
- Vanguard Global Advisers held 13,005 shares of Foghorn Therapeutics worth $46.4K as of Q3 2026.
- Vanguard Global Advisers bought 172 Foghorn Therapeutics shares in Q3 2026, an estimated $906.
- Foghorn Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3092 holding.
- Vanguard Global Advisers first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Foghorn Therapeutics position peaked at $62.6K in Q2 2026.
- 122 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.